Retrobulbar Methylprednisolone as Adjunctive Treatment in Optic Neuritis Trial

Treatment tested

• Methylprednisolone acetate

  Glucocorticoid receptor agonist

Placebo or sham

• Placebo Comparator: Standard treatment + placebo

Other measures (3)

Inclusion Criteria: * Both genres * Age between 18 and 85 years old. * Optic neuritis diagnosis ( relative afferent pupillary defect, acquired dyschromatopsia, low vision, prechiasmatic campimetric defect) * 1 month after symptoms started * If is a bilateral simultaneous optic neuritis the eye with the worst vision will be included. * if is a bilateral sequential optic neuritis the eye with lees 1 month evolution will be included. Exclusion Criteria: * Visual field better than 20/60 at the beginning of the study. * History of optic neuritis in the eye under study. * History of additional ophthalmological or neurological pathology that has caused visual loss in the eye under study. * History of previous treatment with intravenous methylprednisolone since the onset of symptoms. * History of high myopia.

A double-blind prospective randomized clinical trial of treatment for optic neuritis comparing visual outcome of patients treated by standard therapy (intravenous methylprednisolone) + placebo injection and standard therapy + retrobulbar methylprednisolone.